Why the study?
Does recombinant growth hormone treatment affect insulin sensitivity and glucose tolerance in adults with growth hormone deficiency?
Does recombinant growth hormone treatment affect insulin sensitivity and glucose tolerance in adults with growth hormone deficiency?
While growth hormone therapy in adults with GHD induces insulin resistance, it does not inherently cause abnormal glucose tolerance or diabetes mellitus.
Does not warrant avoiding GH therapy in GHD adults over glycemic risk; leaves open prospective trials on long-term diabetes incidence.
Adult growth hormone deficiency (GHD) is a multifactorial disorder in which pituitary dysfunction associated with pituitary adenomas or their treatment plays a major role. The introduction of recombinant growth hormone (GH) for the treatment of GHD has opened up new treatment avenues but has also raised concerns about possible untoward long-term metabolic effects of GH, such as the potential effect of GH on insulin sensitivity and a deterioration in glucose tolerance. Research has shown that GH induces insulin resistance by the stimulation of lipolysis and a concomitant switch from oxidation of glucose to oxidation of lipids, during both acute and chronic treatment. However, although this is a consistent effect of GH therapy, it does not mean per se that it leads to abnormal glucose tolerance and diabetes mellitus. This article discusses this and other potential long-term metabolic effects of GH, and raises a number of questions to be addressed by future research.
No takes yet. Share an insight, caveat, or question.
Groop et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: